Valion Bio, Inc. filed a Form 8-K on November 16, 2026, disclosing the results of a special stockholder meeting held on November 12, 2026, at which stockholders approved three proposals, including an increase in shares authorized under the company's 2021 Equity Incentive Plan and authority for a reverse stock split.
Key Highlights
- Equity plan expanded: Stockholders approved adding 272,000 shares to the Amended and Restated 2021 Equity Incentive Plan, effective upon stockholder approval on November 12, 2026.
- Quorum reached: 1,125,685 shares, or approximately 52.22% of shares entitled to vote, were represented at the Special Meeting.
- Record date shares outstanding: As of October 15, 2026, there were 2,155,637 shares of common stock issued and outstanding and entitled to vote.
- Reverse split authority granted: Stockholders authorized the board to effect a reverse stock split at a ratio of not less than 1-for-2 and not greater than 1-for-12, with the ratio to be determined by the board within twelve months of stockholder approval.
- Adjournment proposal passed: Stockholders approved discretionary authority for the board to adjourn the Special Meeting if necessary to solicit additional proxies, with 686,478 votes for and 438,311 against.
- Preferred stockholders excluded: Holders of Series A, Series B, and Series C Non-Voting Convertible Preferred Stock were not entitled to vote on any matters at the Special Meeting.
Valion Bio Special Meeting: Equity Plan, Reverse Split, and Voting Results
According to the filing, Valion Bio, Inc. (NASDAQ:VBIO) held a virtual special meeting of stockholders on November 12, 2026. The company disclosed that three proposals were put to a vote, each of which received stockholder approval. The Plan Amendment to the Amended and Restated 2021 Equity Incentive Plan received 466,174 votes for, 131,057 votes against, 27 abstentions, and 528,427 broker non-votes, and became effective upon that approval.
The filing also reported that stockholders approved granting the board of directors discretionary authority to implement a reverse stock split of all issued and outstanding shares of common stock at a ratio between 1-for-2 and 1-for-12, with the specific ratio to be determined by the board at any time within twelve months of the date of stockholder approval, without requiring further stockholder action. That proposal received 681,523 votes for, 444,153 votes against, and 9 abstentions, with no broker non-votes reported.
The filing noted that, except for the increase in the share reserve and related conforming changes, the Plan Amendment did not change any other term or provision of the 2021 Plan. The company's Definitive Proxy Statement on Schedule 14A, dated October 16, 2026, contains a fuller description of the 2021 Plan and the Plan Amendment, which is incorporated by reference into Item 5.02 of the Current Report, according to the filing. The report was signed by Dean Zikria, Interim Chief Executive Officer, on November 16, 2026.
What Was Disclosed
Valion Bio disclosed the voting outcomes from its November 12, 2026 special stockholder meeting, covering approval of a 272,000-share equity plan increase, board authority to execute a reverse stock split at a ratio of 1-for-2 to 1-for-12, and an adjournment authorization.




Please wait processing your request...